Biochemical Markers in the Diagnosis of Posttraumatic Knee Osteoarthritis
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Osteoarthritis (OA) is the most common form of arthritis, which is associated with a high risk of disability in patients of any age. That is why the detection of OA in the early stages is of great importance for understanding the progression of the disease and the choice of treatment options.
The objective: to investigate the possibility of using aggrecan for early diagnosis and monitoring the effectiveness of treatment of posttraumatic OA of the knee.
Materials and methods. The study was conducted at the Department of Family Medicine of the Shupyk National Medical Academy of Postgraduate Education included 62 patients with an established diagnosis of post-traumatic OA (PTOA) of the knee, 60 patients in the early period after trauma of the knee (TK) and 12 people – the control group (practically healthy people of the corresponding age). All patients underwent a comprehensive examination prior to the start of treatment, after 2 and 4 weeks, and also after 6 and 12 months. Patients in the control group study was performed once. Patients included in the study were divided into groups: І group – patients who received complex treatment (NSAIDs, physical exercises, complex physiotherapy for patients with PTOA and NSAIDs, complex physiotherapy for patients with TK) in combination with 3 intra-articular injections of PAP; Group ІІ – patients who received only complex treatment. The processing of the obtained results was performed using the Microsoft Office 2010 (MS Excel and Windows). Statistical analysis was performed using the SPSS v.21.
Results. During the study, the analysis of aggrecan levels in the course of treatment showed that all patients with TK had an increase aggrecan in serum 2 weeks after the treatment, with a gradual decrease in this indicator from 4 weeks after treatment. During the dynamic observation, the average level of serum aggrecan in patients with PTOA in the group with combined treatment tended to gradually decrease with the lowest rates 12 months after treatment, while in the group of complex treatment there were no significant fluctuations in the level of aggrecan over the entire study period.
Conclusions. А high level of aggrecan is determined in patients in the early stages after TK. In the standard treatment of PTOA, no significant fluctuations in the level of aggrecan in the blood serum were found, which testifies in favor of continuous destruction of articular cartilage. There is a gradual decrease in the content of aggrecan in patients using PAP with TK and PTOA, which may indicate a decrease in degenerative processes in cartilage under the influence of platelet biologically active substances.##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Patra D, Sandell LJ. Evolving biomarkers in osteoarthritis. J of Knee Surgery. 2011;24(4):241–249. http://dx.doi.org/10.1055/s-0031-1286192
Давидкіна И.Л., Щукіна Ю.В. Поліклінічна терапія: підручник ГЕОТАР-Медія, 2013. – 688 с.
Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(1):26–35. https://doi.org/10.1002/art.23176
Mobasheri A, Bay-Jensen A-C, Spil WE, Larkin J, Levesque MC. Osteoarthritis Year in Review 2016: biomarkers (biochemical markers). Osteoarthritis and cartilage. 2017;25(2):199–208. https://doi.org/10.1016/j.joca.2016.12.016
Mabey T, Honsawek S, Cytokines as biochemical markers for knee osteoarthritis. World J Orthop. 2015;6(1):95–105. https://doi.org/10.5312/wjo.v6.i1.95
Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2011;7:33–42. https://doi.org/10.1038/nrrheum.2010.196
Mort JS, Geng Y, Fisher WD, Roughley PJ. Aggrecan heterogeneity in articular cartilage from patients with osteoarthritis. BMC Musculoskelet Disord. 2016;17:89. https://doi.org/10.1186/s12891-016-0944-8
Kiani C, Chen L, Wu YJ, Yee AJ, Yang BB. Structure and function of aggrecan. Cell Research. 2002;12:19–32. https://doi.org/10.1038/sj.cr.7290106
Huang K, Wu LD. Aggrecanase and Aggrecan Degradation in Osteoarthritis: a Review. J Int Med Res. 2008;36:1149–1160. https://doi.org/10.1177/147323000803600601
Camp CL, Stuart MJ, Krych AJ. Current concepts of articular cartilage restoration techniques in the knee. Sports Health. 2014;6(3):265–273. https://dx.doi.org/10.1177%2F1941738113508917
Roughley PJ, Mort JS. The role of aggrecan in normal and osteoarthritic cartilage. J Exp Orthop. 2014;1:8. https://dx.doi.org/10.1186%2Fs40634-014-0008-7
Shi S, Mercer S, Eckert GJ, Trippel SB. Regulation of articular chondrocyte aggrecan and collagen gene expression by multiple growth factor gene transfer. J Orthop Res. 2012;30(7):1026–1031. https://doi.org/10.1002/jor.22036
Sunitha RV, Munirathnam NE. Platelet-rich fibrin: evolution of a second-generation platelet concentrate. Indian J Dent Res. 2008;19(1):42–46. Full text
Kevy SV, Jacobson MS. Comparison of methods for point of care preparation of autologous platelet gel. J Extra Corpor Technol. 2004;36(1):28–35. PDF
Pearle AD, Warren RF, Rodeo SA. Basic science of articular cartilage and osteoarthritis. Clinics in Sports Medicine. 2005;24(1):1–12. https://doi.org/10.1016/j.csm.2004.08.007
Lorenzo P, Bayliss MT, Heinegård D. Altered patterns and synthesis of extracellular matrix macromolecules in early osteoarthritis. Matrix Biology. 2004;23(6):381–391. https://doi.org/10.1016/j.matbio.2004.07.007
